Inhaled Form of Insulin for Diabetics Studied
Posted on: Friday, 9 September 2005, 06:00 CDT
WASHINGTON -- A government advisory committee is scrutinizing an inhaled form of insulin that is designed to help millions of people with diabetes who now rely on injections to control their blood sugar.
Chief concerns about the drug involve its long-term effects on the lungs, as well as whether it is safe and effective on people who smoke or have lung disease, according to documents released by the Food and Drug Administration.
The inhaled insulin, called Exubera, could help diabetics who are reluctant to take injections. The insulin is being developed by Pfizer, Sanofi-Aventis and Nektar Therapeutics.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee was to consider today whether to recommend the drug to government regulators for approval. The FDA usually follows the recommendations of its advisory committees, but it isn't required to.
Source: Cincinnati Post
Related Articles
- Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
- Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
- Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
- Targanta Announces Review of Oritavancin at FDA Anti-Infective Drugs Advisory Committee Meeting
- Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June
- Oncologic Drugs Advisory Committee Recommends FDA Wait for Overall Survival Analysis of Satraplatin for Treatment of Hormone-Refractory Prostate Cancer
- IDM Pharma Inc. Announces Oncologic Drugs Advisory Committee Meeting for Junovan(TM) (Mifamurtide) Will Take Place on May 9, 2007
- Amgen to Participate in Oncologic Drugs Advisory Committee in May
- Cubist Pharmaceuticals Announces Posting of Briefing Documents for FDA Anti-Infective Drugs Advisory Committee (AIDAC) Meeting; AIDAC Meeting to Review CUBICIN sNDA is Monday, March 6th
- OSI Pharmaceuticals Announces Tarceva(R) to Be Reviewed By the FDA's Oncologic Drugs Advisory Committee for Use in Pancreatic Cancer
 |
 |
User Comments (0)
RSS Feeds